Pharmaceuticals, Biotechnology & Life Sciences

S&P 500’s modest 0.1 % decline amid a flurry of bank earnings reports.

Aurora Cannabis revamps leadership to boost governance and operational efficiency, aiming for sustainable growth in the evolving medical cannabis market.

Discover how Prelude Therapeutics’ oral small‑molecule cancer drugs could transform treatment, plus the latest stock trends and investment outlook.

Explore how Regencell Bioscience harnesses traditional medicine to tackle neurocognitive disorders, its Nasdaq journey, and the future of holistic biotech innovation.

Explore how SELLAS Life Sciences Group Inc. is advancing late‑stage oncology drugs, driving biopharma innovation and improving cancer treatment worldwide.

Explore Pfizer’s 2026 stock trend, market value, and R&D focus on precision oncology—see how the pharma giant’s strategy drives growth and investment.

GSK PLC prepares to report Q4 earnings on Oct 28, with analysts projecting EPS of £0.505, while unveiling an $800 M U.S. expansion to boost vaccine capacity and create jobs.

Avantor Inc’s shaky stock, negative P/E, and 52‑week volatility highlight a key healthcare player at a crossroads – what strategies can revitalize its profitability?

Insilico Medicine Cayman Top leads medical AI in drug discovery, advancing therapy candidates and data‑driven diagnostics to boost patient outcomes.

Gilead Sciences’ stock gains reflect investor confidence in its drug pipeline, driving a broader healthcare sector rebound in late October 2026.